ATG-010

also known as Selinexor

targets XPO1 via inhibition

Developed for: diffuse large B-cell lymphoma · endometrial cancer · indolent B-cell non-Hodgkin lymphoma · mature T-cell and NK-cell non-Hodgkin lymphoma · ovarian cancer · peripheral T-cell lymphoma, not otherwise specified · refractory plasma cell neoplasm · relapsed/refractory diffuse large B-cell lymphoma
Investigated by: Antengene Corporation · Qi Zhou

Trials 6

today NCT05265975 · Ph 1/2 NCT05354362 · Ph 1 NCT04998760 · Ph 2 NCT04425070 · Ph 1/2 NCT03992339 · Ph 2 NCT03944057 · Ph 2

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT05354362	Mar 2022 → Feb 2023	relapsed/refractory diffuse large B-cell lymphoma	Antengene Corporation	Terminated	No outcome recorded Stop: Business
Phase 1/22 trials
Phase 1/2	NCT05265975	Apr 2022 → Dec 2024	diffuse large B-cell lymphoma, indolent B-cell non-Hodgkin lymphoma	Antengene Corporation	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT04425070	Aug 2020 → Dec 2025	mature T-cell and NK-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified	Antengene Corporation	Terminated	No outcome recorded Stop: Business
Phase 23 trials
Phase 2	NCT04998760	Aug 2021 → Jan 2024	endometrial cancer, ovarian cancer	Qi Zhou	Unknown	No outcome recorded
Phase 2	NCT03992339	Apr 2020 → May 2023	diffuse large B-cell lymphoma	Antengene Corporation	Completed	No outcome recorded
Phase 2	NCT03944057	Sep 2019 → Feb 2022	refractory plasma cell neoplasm	Antengene Corporation	Completed	No outcome recorded

Press releases naming this drug 56 releases

Date	Issuer	Release
2026-09-14	Antengene Corporation	Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG‑037 Combined with Selinexor in Cancer Gene Therapy antengene.com ↗
2025-03-05	Antengene Corporation	XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene’s Commercial Presence in APAC antengene.com ↗
2024-12-10	Antengene Corporation	Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024 antengene.com ↗
2024-11-06	Antengene Corporation	Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 antengene.com ↗
2024-10-18	Antengene Corporation	Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country antengene.com ↗
2024-09-23	Antengene Corporation	Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand antengene.com ↗
2024-08-06	Antengene Corporation	Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia antengene.com ↗
2024-07-05	Antengene Corporation	XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country antengene.com ↗
2024-06-26	Antengene Corporation	Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea antengene.com ↗
2023-08-11	Antengene Corporation	Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO® (selinexor) in the Mainland of China antengene.com ↗
2022-11-07	Antengene Corporation	Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting antengene.com ↗
2022-06-27	Antengene Corporation	Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma antengene.com ↗
2022-05-23	Antengene Corporation	Antengene Announces First Patient Dosed in the Phase I II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas antengene.com ↗
2022-05-14	Antengene Corporation	Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress antengene.com ↗
2022-05-14	Antengene Corporation	Antengene Announces Commercial Availability of XPOVIO® (Selinexor) Prescribed for the First Time Across Mainland China antengene.com ↗
2022-04-06	Antengene Corporation	Antengene’s Pivotal “MARCH” Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine antengene.com ↗
2021-12-14	Antengene Corporation	Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) antengene.com ↗
2021-11-19	Antengene Corporation	Antengene Announces IND Approval in China for a Phase I II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma antengene.com ↗
2021-11-09	Antengene Corporation	Antengene to Release Preliminary Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of Peripheral T-Cell Lymphoma and NKT-Cell Lymphoma at the 2021 antengene.com ↗
2021-11-02	Antengene Corporation	Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma antengene.com ↗
2021-08-24	Antengene Corporation	Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China antengene.com ↗
2021-07-31	Antengene Corporation	Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma antengene.com ↗
2021-07-14	Antengene Corporation	Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies antengene.com ↗
2021-07-06	Antengene Corporation	Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF) antengene.com ↗
2021-06-04	Antengene Corporation	Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 antengene.com ↗
2021-06-02	Antengene Corporation	Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021 antengene.com ↗
2021-06-02	Antengene Corporation	Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021 antengene.com ↗
2021-05-12	Antengene Corporation	Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer antengene.com ↗
2021-05-06	Antengene Corporation	Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines antengene.com ↗
2021-04-29	Antengene Corporation	Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment antengene.com ↗
2021-04-22	Antengene Corporation	Treatment with Selinexor in Advanced Liposarcoma Demonstrates Clinically Important Reduction in Pain with Improved HRQoL Outcomes antengene.com ↗
2021-04-12	Antengene Corporation	Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL antengene.com ↗
2021-02-24	Antengene Corporation	Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China’s NMPA antengene.com ↗
2021-01-28	Antengene Corporation	Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM antengene.com ↗
2021-01-25	Antengene Corporation	Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study antengene.com ↗
2021-01-11	Antengene Corporation	Restore the core! Selinexor (ATG-010), a first-in-class drug for multiple myeloma, to be launched in Hainan Free Trade Port antengene.com ↗
2021-01-05	Antengene Corporation	Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer antengene.com ↗
2021-01-04	Antengene Corporation	Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL antengene.com ↗
2020-12-21	Antengene Corporation	Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy antengene.com ↗
2020-12-18	Antengene Corporation	Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM antengene.com ↗
2020-12-11	Antengene Corporation	Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM antengene.com ↗
2020-12-07	Antengene Corporation	Antengene Announces Acceptance of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study antengene.com ↗
2020-12-03	Antengene Corporation	Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL antengene.com ↗
2020-09-14	Antengene Corporation	Antengene Announces First Patient Dosed with ATG-010 (selinexor) for Relapsed or Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma antengene.com ↗
2020-04-24	Antengene Corporation	Antengene Announces First Patient Dosed in China Registration Trial of ATG-010 (selinexor) for Relapsed or Refractory Diffuse Large B-cell Lymphoma (RR DLBCL) antengene.com ↗
2020-03-12	Antengene Corporation	Phase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China antengene.com ↗
2020-03-05	Antengene Corporation	Phase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China antengene.com ↗
2020-03-02	Antengene Corporation	Phase 3 Clinical Study of Novel Selective Inhibitor of Nuclear Export Selinexor with New Combination Therapy for Multiple Myeloma Meets Primary Endpoint antengene.com ↗
2020-01-20	Antengene Corporation	News Express! The Clinical Trial of ATG-010 for Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Has Been Approved antengene.com ↗
2019-09-21	Antengene Corporation	Latest Progress in the treatment of blood cancer with Selinexor, a selective inhibitor of nuclear export antengene.com ↗
2019-07-03	Antengene Corporation	Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma antengene.com ↗
2019-01-28	Antengene Corporation	ATG-010, China’s first Selective Inhibitor of Nuclear Export obtains IND approval for the treatment of multiple myeloma antengene.com ↗
2018-09-22	Antengene Corporation	Antengene publishes clinical data on ATG-010 (Selinexor) for the treatment of refractory and/or relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma at the Annual Meeting of Chinese Society of Clinical Oncology antengene.com ↗
2018-08-07	Antengene Corporation	Karyopharm，Antengene Corporation’s Strategic Partner, Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor （ATG-010）as a Treatment for Patients with Penta-Refractory Multiple Myeloma antengene.com ↗
2018-07-18	Antengene Corporation	Antengene Corporation’s Strategic Partner, Karyopharm Therapeutics, Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma antengene.com ↗
2018-05-24	Antengene Corporation	Antengene and Karyopharm Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia antengene.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

Field	Value	Cited text
Known as	ATG 010	“ATG 010 40mg/once, will be given on Days 1, 8, and 15 of each cycle” NCT04425070 ↗ 6 “ATG-010 60 mg/once, oral, on Days 4 and 11.” NCT04425070 ↗ NCT05354362 ↗ NCT05265975 ↗ NCT03944057 ↗ NCT03992339 ↗ NCT04998760 ↗
Known as	Selinexor	“Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial.” PMID 42438166 ↗ Aug 2026
Action	Inhibit	“inhibition of exportin-1 (XPO1)” PMID 42438166 ↗ Aug 2026
Route	Oral	“ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles” NCT03944057 ↗
Target	XPO1	“inhibition of exportin-1 (XPO1)” PMID 42438166 ↗ Aug 2026